Skip to content

Recovery

Glepaglutide

Also called ZP1848

InjectableEvidence AOnce a week
Half-life
50hours
Typical vial
10mg
Research amounts
10–10mg

per administration

Common schedule
Once a week
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded300units dialled
Concentration
3.33mg/mL
Volume per draw
3mL
Units to dial
300
Doses per cartridge
1

This is 300 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.

Dial range varies by pen; 1–60 units is the common configuration.

Vial label

Copy this into your label printer.

Published research contexts for Glepaglutide describe 1010 mg per administration. Descriptive only, not a recommendation.

Roughly two days from limited reports; the figure is thin and estimates vary.

Dosing schedule

How Glepaglutide is commonly stepped up, for reference only.

These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.

PhaseAmountFrequencyRoute
Reported doseThe long half-life supports weekly spacing; the EASE program ran 10 mg once or twice weekly.10 mgOnce or twice weeklySubQ

Modelled level — once a week

1× is the peak after a single dose.

Steady-state peak
1.08× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
10.4days

About five half-lives

Administrations
1/ week

Where these numbers come from

  • Naimi RM et al., Lancet Gastroenterology & Hepatology 2019 (EASE-1)Subcutaneous glepaglutide (ZP1848) assessed for intestinal absorption in short-bowel syndrome; the later EASE program used 10 mg once or twice weekly.

Next steps

Others in recovery